Categories
Change Password!
Reset Password!
As the targeted stimuli‐responsive nanomedicines effectively postpone RA
progression with less severe adverse events, these can become a substitute for
the conventional medicines used for RA management.
These days’ nanotechnology‐based medicines, the nanomedicines (NMs) have gained attention as an effective treatment strategy to counter health issues like arthritis. Pre‐clinical research scientists, as well as physicians from all over the globe, support this approach. Therefore, Lu Liu and colleagues found out the targeted stimuli‐responsive NMs as a rheumatoid arthritis (RA) treatment approach in the last five years. Various milestones have been achieved in the clinical treatment of RA, but these therapies present certain shortcomings which begin from the adaptive treatment tolerance (ATT) following the long‐term drug use which leads to reduced efficacy, increasing sustained drug dose and critical adverse events. There is a need to establish innovative therapeutic approaches to overcome these challenges.
The nanotechnology‐based nanomedicines (NMs) are
emerging as treatment for RA. One of the fundamental concepts in building more
convenient multifunctional NMs formulations for efficient RA treatment is its
targeted stimuli‐responsive features. Because of NMs delivery and on‐demand
liberation of medicaments at targets in response to internal or external
stimuli associated with the RA pathophysiology helps to postpone the RA
progression efficiently and with no side effects on healthy tissues.
Biotechnology Journal
Move to Nano‐Arthrology: Targeted Stimuli‐Responsive Nanomedicines Combat Adaptive Treatment Tolerance (ATT) of Rheumatoid Arthritis
Lu Liu et al.
Comments (0)